Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.57 |
| ▸ | CA2 | P00918 | 12/20 | 0.57 |
| ▸ | CA9 | Q16790 | 11/20 | 0.57 |
| ▸ | CA12 | O43570 | 10/20 | 0.57 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997856 | 0.86 | PTGS2 (0.48) | CA1CA2CA9CA12PTPN7 | |
| SCHEMBL10033645 | 0.83 | ALDH1A1 (0.50) | KMT2AALDH1A1MEN1TSHR | |
| SCHEMBL10033649 | 0.79 | ALDH1A1 (0.46) | KMT2AALDH1A1MEN1 | |
| SCHEMBL10033639 | 0.78 | NAPRT (0.58) | KMT2AALDH1A1MEN1 | |
| SCHEMBL10033647 | 0.77 | NPSR1 (0.43) | CA2KMT2AALDH1A1MEN1HPGD | |
| SCHEMBL14997857 | 0.76 | MAPT (0.58) | KMT2AALDH1A1MEN1 | |
| SCHEMBL10033646 | 0.76 | RORC (0.50) | KMT2AALDH1A1MEN1TSHR | |
| SCHEMBL10033637 | 0.74 | MAPT (0.47) | KMT2AALDH1A1MEN1HPGDTSHR | |
| Iodide SCHEMBL5062682 | 0.74 | CA1 (0.59) | CA1CA2CA9CA12PTPN7 | |
| SCHEMBL10033640 | 0.74 | MEN1 (0.57) | CA1CA2KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742156-B2 | Anti-viral carbamimidothioic acid esters | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2014-06-03 | — | — | US | disclosed |
| US-8742156-B2 | Anti-viral carbamimidothioic acid esters | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2014-06-03 | — | — | US | disclosed |
| US-20130143961-A1 | ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS | BRITISH COLUMBIA CANCER AGENCY (CA) | 2013-06-06 | — | — | US | disclosed |
| US-20130143961-A1 | ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS | BRITISH COLUMBIA CANCER AGENCY (CA) | 2013-06-06 | — | — | US | disclosed |
| WO-2012021991-A1 | ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS | VERSITECH LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143961-A1 | ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS | NAT10, RNGTT, NSUN2 | CA1 2147/4885CA2 677/4885CA9 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.